Introduction
The cytochrome P450 2C9 (CYP2C9) enzyme metabolizes both warfarin and arachidonic acid.
1,2 The CYP2C9*2 (rs.1799853) and CYP2C9*3 (rs.1057910) polymorphisms cause decreased warfarin metabolism, 3 and genotyping for these two polymorphisms has already entered clinical practice to adjust for individual dosage of warfarin. 4 It is therefore likely that these genotypes also affect metabolism of arachidonic acid, 5 and consequently could influence development of atherosclerosis in which arachidonic acid metabolites may have a major role. muscle cells and thereby vasodilatation. Epoxyeicosatrienoic acids are also involved in neuroprotection and cardioprotection after ischemia, 9 and possess vascular antiinflammatory effects 6 important in the protection against atherosclerosis. 7, 8 CYP2C9 is mainly expressed in the liver, but is also expressed in the blood vessel wall. 10 We therefore hypothesized that genetic polymorphisms in CYP2C9 with decreased enzyme activity associate with increased risk of atherosclerosis and related diseases. We first compared ankle brachial systolic blood pressure index and plasma concentration of C-reactive protein (CRP), a marker of cardiovascular health, 11 across genotypes to detect any differences in subclinical atherosclerosis. Second, we calculated the risk of ischemic heart disease (IHD), myocardial infarction (MI), ischemic cerebrovascular disease (ICVD) and ischemic stroke (IS) by genotype. Third, we calculated risk of early death after a diagnosis of IHD by genotype.
Participants and methods

Participants
Three independent studies were included. Participants gave written informed consent and the studies were approved by Danish ethics committees (nos. KF-100 2039/91, KF-01-144/01, H-KF-01-144/01, KA-93125 and KA-99039). In all three studies, only Caucasians of Danish descent were included and there was no overlap of individuals between studies.
The Copenhagen City Heart Study (CCHS) is a population-based study initiated in 1976-1978. 12,13 Participants aged 20 years or above were randomly drawn from the Copenhagen Population Register and were reexamined in 1981-1983, 1991-1994 and 2001-2003 . DNA was sampled in the last two examinations. Participants filled in a selfadministered questionnaire relating to lifestyle and health before physical examination and blood sampling. We included 10 398 participants.
The Copenhagen General Population Study (CGPS) is an ongoing population-based study initiated in 2003. 12, 14, 15 Participants aged 20 years or above were randomly drawn from the Copenhagen Population Register. Data on each participant collected in this study are identical to those in the CCHS. We included 21 629 participants.
The Copenhagen Ischemic Heart Disease Study (CIHDS) is a case-control study in which cases were collected from 1991 and is still ongoing. 14, 15 Inclusion criteria for cases are characteristic symptomatology of angina pectoris and at least one of the following: previous MI, stenosis/atherosclerosis on coronary angiography or a positive exercise electrocardiography test. We included 5089 cases. Controls were 14 904 individuals from the general population free of ischemic vascular disease (ascertained like in the CGPS) and matched with cases according to age and sex.
Covariates
Participants were divided into smokers and never smokers, smokers being former and current smokers. Participants were also divided into two groups according to use of alcohol: abstainers and drinkers. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ), and participants were classified as underweight (BMIo18), normal weight (BMI 18-25), overweight (BMI425-30) and obese (BMI430). Blood pressure was measured and participants were categorized into normotensive (systolic blood pressure o140 mm Hg and diastolic blood pressure o90 mm Hg), mildly hypertensive (systolic blood pressure 140-159 or diastolic blood pressure 90-99 mm Hg), moderately hypertensive (systolic blood pressure 160-179 or diastolic blood pressure 100-109 mm Hg) and severely hypertensive (systolic blood pressure 4179 mm Hg or diastolic blood pressure 4109 mm Hg). Participants were also categorized as passive and active, passive being participants with predominantly sitting work and physically passive in their spare time. End points Ankle brachial index was calculated as the lowest of the two ankle systolic blood pressures divided by the highest of the two brachial systolic blood pressures. High-sensitivity CRP was measured in plasma by nephelometric or turbidimetric assays. 15, 16 Information with regard to IHD, MI, ICVD and IS was obtained by linking the participants to the national Danish Patient Registry and the national Danish Causes of Death Registry, using each participant's unique Central Person Register number. [12] [13] [14] [15] [16] The diagnoses were defined according to the World Health Organization International Classification of Diseases, 8th and 10th editions. IHD was ICD-8 410-414 and ICD-10 I20-I25. MI (ICD-8 410 and ICD-10 I21-I22) required at least two of the following: characteristic chest pain, elevated cardiac enzymes or MI-specific electrocardiographic changes. ICVD was ICD-8 431-438 and ICD-10 I61-I69 and G45. IS was validated as described. 17 Genotyping Two single-nucleotide polymorphisms in CYP2C9 (CYP2C9*2 rs.1799853 and CYP2C9*3 rs.1057910) were genotyped with the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). For both polymorphisms, sequences of primers and probes were blasted against the human genome to exclude the possibility of unspecific binding. Control sequencing was performed to verify the genotyping for both polymorphisms, and to exclude the possibility for coamplification of similar genes; in case of more than one amplified gene, the sequence chromatogram would show multiple positions with heterozygosity; however, this was never the case. Genotyping was performed as singleplex in a 384-well format, including a negative water control and three controls being noncarrier, heterozygous and homozygous.
Statistical analysis
Data analysis was performed using STATA/SE 10.1 (College Station, TX, USA). P-values were considered statistically significant if two-sided values were o0.05. The two polymorphisms in CYP2C9 were combined to form two groups: noncarriers being homozygous for the commonest CYP2C9*1 variant and carriers with one or more alleles with CYP2C9*2 and CYP2C9*3 variants combined.
First, we analyzed ankle brachial index and plasma CRP levels across carriers versus noncarriers, using box plots to present the distribution and the Mann-Whitney U-test to calculate P-values. Second, we analyzed the association of carriers versus noncarriers on risk of IHD, MI, ICVD and IS in the prospective CCHS using Cox proportional hazard regression with age as time scale, using delayed entry and adjusted for sex or multifactorially for all covariates (sex, smoking status, alcohol use, BMI, plasma cholesterol, plasma glucose, hypertension and physical activity) to estimate hazard ratios. Follow-up began at entry into the CCHS and ended at event, death or 9 July 2007, whichever came first. Participants with events before study entry were excluded from the particular analysis. Third, we analyzed the association of carriers versus noncarriers on risk of IHD, MI, ICVD and IS in the CGPS and the CIHDS, using conditional logistic regression with sex and age as strata alone, or adjusted for all covariates mentioned above. Thereafter, prognosis after an IHD diagnosis was calculated in the CCHS and the CIHDS as hazard ratios for early death using Cox proportional hazard regression adjusted for sex and age at diagnosis. Entry began at time of diagnosis and ended at death or on 9 July 2007, whichever came first. Power calculations were performed with STATA/SE 10.1 (prospective study) and NCSS PASS 2001 (cross-sectional and case-control study).
All authors had full access to and take full responsibility for the integrity of data. All authors have read and agreed to the paper as written. 
Results
The CCHS included 33.9% carriers, the CGPS 34.3% carriers and the CIHDS included 33.6% carriers. For risk factors of atherosclerosis, there was no observed difference between CYP2C9 carriers versus noncarriers in any of the three studies (Table 1) . CYP2C9 carriers versus noncarriers did not differ with regard to the ankle brachial index or plasma CRP levels ( Figure 1) .
We did not detect any convincing change of risk across genotype for IHD, MI, ICVD or IS in any of the three studies (Tables 2-4 ). In the CGPS, the age-and sex-adjusted odds ratio for IHD in carriers versus noncarriers was 0.9 (95% confidence interval (CI): 0.8-1.0) and remained significant after multifactorial adjustment (Table 3) . However, the reduced risk of IHD could not be confirmed in both the CCHS and the CIHDS (Tables 2 and 4) . Furthermore, subdividing carriers in the CGHS into two groups, heterozygotes and homozygotes/ compound heterozygotes, and recalculating odds ratios for IHD did not show any step-wise decrease in risk on the basis of allele dosage (data not shown). Therefore, we consider the reduced risk of IHD in the CGPS as a chance finding. There was no association in carriers versus noncarriers on risk of MI, ICVD and IS in any of the three studies.
In carriers versus noncarriers of the CCHS, we had 90% power to exclude hazard ratios lower/higher than 0.9/1.2 for IHD, 0.8/1.1 for MI, 0.8/1.2 for ICVD and 0.8/1.2 for IS ( Table 2 ). Corresponding odds ratios in the CGPS were 0.9/1.1 for IHD, 0.8/1.2 for MI, 0.8/1.2 for ICVD and 0.7/1.4 for IS (Table 3) . Finally, corresponding odds ratios in the CIHDS were 0.9/1.1 for both IHD and MI (Table 4) . Abbreviations: CI, confidence interval; ICVD, ischemic cerebrovascular disease; IHD, ischemic heart disease; IS, ischemic stroke; MI, myocardial infarction. Number of participants and events varied slightly from end point to end point because participants with an end point before start of follow-up were excluded from that specific analysis, but not from analysis of other end point. P-values derived from likelihood ratio from z-statistics of the Cox regression model. The hazard ratios for risk of early death after an IHD and MI diagnosis in carriers versus noncarriers of both the CCHS and the CIHDS did not differ from 1.0 (Table 5) .
Discussion
In this study, we hypothesized that polymorphisms in CYP2C9 affecting enzyme activity associate with risk of subclinical atherosclerosis (reduced ankle brachial index and elevated plasma CRP), ischemic vascular disease (IHD, MI, ICVD and IS) and risk of early death after an IHD diagnosis. This hypothesis was rebutted with considerable power in two large independent cohorts of the general population and in one case-control study among patients with IHD, totaling more than 52 000 Caucasian individuals.
These findings are surprising as there are convincing data supporting that CYP2C9 metabolize arachidonic acid into biologically active epoxyeicosatrienoic acids, 1, 18 and as CYP2C9*2 and CYP2C9*3 polymorphisms are known to alter enzyme activity. 3 However, we cannot exclude the possibility that the explanation for our negative findings could be because the catalytic site of CYP2C9 for warfarin, 2 affected by the CYP2C9*2 and CYP2C9*3 polymorphisms, may be located in another area of the protein than the catalytic site for arachidonic acid. This is currently not known. Alternatively, levels of epoxyeicosatrienoic acids may not be important for the development of atherosclerosis, in contrast to that suggested previously. 8 Our findings contrast some, 19, 20 but not all, studies. [21] [22] [23] [24] A Swedish study published in 2003 reported a modest increased risk of MI among women carrying CYP2C9 polymorphisms (172 MI cases/1503 controls). 20 Another case-control study, however, found that CYP2C9 polymorphisms in men were associated with decreased risk for MI (403 MI cases/431 controls), but found no risk association in women. 19 There has also been a reported higher risk of MI among women receiving different drugs metabolized by CYP2C9 in the prospective Rotterdam Study (hazard ratio: 2.5, 95% CI: 1.6-4.0, 5744 participants), but this study found no association between MI and CYP2C9 polymorphisms in either men or women overall. 25 In that article, it was speculated that the mechanism for the gender difference observed in several studies might be because of the difference in estrogen levels; 25 however, we did not find any consistency for sex interaction between the CYP2C9 genotype and any of the end points in either of our three studies (data not shown). Other studies have not succeeded in finding any evidence between CYP2C9 Abbreviations: CCHS, Copenhagen City Heart Study; CI, confidence interval; CIHDS, Copenhagen Ischemic Heart Disease Study; IHD, ischemic heart disease; MI, myocardial infarction. For the Copenhagen City Heart Study only participants with diagnosis after blood sampling were included. P-values derived from likelihood ratio from z-statistics of the Cox regression model. CYP2C9*2 and CYP2C9*3 and risk of atherosclerosis D Kaur-Knudsen et al polymorphisms and ischemic vascular disease, [21] [22] [23] [24] in accordance with this study.
Erroneous genotyping could explain a failure to detect a true association, but we consider this highly unlikely in our study as we included positive controls in all genotype reactions, and also because genotypes were confirmed by sequencing. Furthermore, both polymorphisms were in Hardy-Weinberg equilibrium (P40.25) in all three studies, and our genotype frequencies are in accordance with other studies of Caucasians. 26 We have a number of strengths in our studies. In all three studies, we had a homogenous population with 100% Caucasians, important for analyses, including CYP2C9*2 and CYP2C9*3 polymorphisms, as these are primarily found in a Caucasian population. 27 We had the unique possibility of examining our hypotheses in three very large and independent studies with validated end points, enabling us to test our hypotheses in a prospective (CCHS), a crosssectional (CGPS) and a case-control study (CIHDS), totaling more than 52 000 individuals. This gave us sufficient power to reject all hypotheses.
In conclusion, in three independent studies totaling more than 52 000 individuals, we found no association between CYP2C9*2 and CYP2C9*3 and risk of subclinical atherosclerosis, IHD, MI, ICVD, IS or death after IHD. For all end points, we could exclude even minor changes in risk of disease with 90% power.
